Thursday, December 26, 2013

Spiroindolone that inhibits PfATPase4 is a potent, cidal Inhibitor of Toxoplasma gondii tachyzoites in vitro and in vivo

 2013 Dec 23. [Epub ahead of print]

Spiroindolone that inhibits PfATPase4 is a potent, cidal Inhibitor of Toxoplasma gondii tachyzoites in vitro and in vivo

Zhou Y, Fomovska A, Muench S, Lai BS, Mui E, McLeod R.

Abstract

Herein, we show that spiroindolone, an effective treatment of Plasmodia, is also active against T. gondii tachyzoites. In vitro, spiroindolone NITD 609 is cidal for tachyzoites (IC50= 1μM) and not toxic to human cells at ≥10μM. Two daily oral doses of 100mg/Kg reduced parasite burden by 90% (p=0.002), measured 3 days after last dose. This inhibition of T. gondii tachyzoites in vitro and in vivo indicates spiroindolone is a promising lead candidate for further medicine development.
PMID:
 
24366743
 
[PubMed - as supplied by publisher]
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)